Baker et al. tested a mucosal adjuvant, the double mutant heat-labile toxin of E. coli (dmLT), with an OMP vaccine, increasing IgG and IL-17A production and achieving a 53% survival rate in a pneumonia model [147]. The gene discussed is IL17A; the disease is pneumonia.